Company Filing History:
1 out of 832,912 Years Active: 2004
Title: The Innovations of David John Hansman in Pneumococcal Vaccines
Introduction: David John Hansman, a prominent inventor based in Rose Park, S.A. 5067, Australia, has made significant contributions to the field of immunology. With his innovative work focused on pneumolysin mutants, Hansman's research aims to enhance vaccine efficacy against pneumococcal diseases. His notable patent reflects a commitment to advancing medical science and public health.
Latest Patents: Hansman holds a patent titled "Pneumolysin mutants and pneumococcal vaccines made therefrom." This invention involves the construction of non-toxic mutants of pneumolysin, achieved through specific amino acid substitutions. These mutants are designed to elicit a robust immune response in animals that is reactive to the wild-type pneumolysin. Notably, the patent also includes the development of vaccines for humans based on these mutants, incorporating conjugates with pneumococcal capsular polysaccharides.
Career Highlights: Throughout his career, David John Hansman has demonstrated exceptional dedication to research and innovation. His work has not only contributed to scientific understanding but has also paved the way for potential therapeutic advancements in vaccines. The successful creation of non-toxic pneumolysin mutants is a testament to his expertise and innovative thinking in biotechnology.
Collaborations: Hansman collaborates with colleague Graham John Boulnois, a partnership that fosters an environment of creativity and shared knowledge. This collaboration enhances the research output and allows for a comprehensive approach to tackling complex challenges in vaccine development.
Conclusion: David John Hansman's contributions to the field of pneumococcal vaccines illustrate the transformative power of innovation in medicine. His patented work on pneumolysin mutants is an essential step toward improving vaccine strategies, ultimately benefiting public health. As a dedicated inventor, Hansman’s efforts continue to inspire future advancements in immunology and vaccine research.